GLP‐1 RA treatment on BMD in T2D people was first evaluated in a retrospective cohort study that included people with diabetes and compromised bone quality (T‐score < −1), the effects of switching from a DPP‐4i to a GLP‐1 RA were examined. This evidence concerns the gene GLP1R and diabetes mellitus.